ADARx Pharmaceuticals
PublicADARx Pharmaceuticals is now publicly traded
The data on this page reflects ADARx Pharmaceuticals's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Strategic
May 14, 2025
Total Funding Raised
$666.5M
Company Overview
ADARx Pharmaceuticals is a biotechnology company that develops innovative therapeutics using a proprietary RNA targeting platform and advanced delivery technologies to treat genetic, cardiovascular, and central nervous system diseases.
Sector
Biotech
Verticals
HealthTech, Life Sciences
AI Layer
Non-AI
Keywords
ADARx Pharmaceuticals Comparables
Compare ADARx Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sanegene Bio | 83% | |
| Arrowhead Pharmaceuticals | 81% | |
| Silence Therapeutics plc | 78% |
For institutional investors. Book with your work email.
ADARx Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | May 14, 2025 | ||||
| Series C | Aug 9, 2023 | ||||
| Series B Extension | Jan 20, 2023 | ||||
| Series B | Sep 8, 2021 | ||||
| Series A | Nov 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ADARx Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C |
| Sirona Capital | Series B, Series B Extension |
| Bain Capital Life Sciences | Series C |
| TCG Crossover | Series C |
| Cormorant Asset Management | Series C |
| OrbiMed | Series B Extension, Series C, Series A, Series B |
| Commodore Capital | Series C |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 26, 2026
ADARx Pharmaceuticals, Inc. receives $535M through an IPO and private placement in Sep '26 to support clinical development of its siRNA therapies beyond the liver.
- has_valuationSep 26, 2026
On Sep 25th '26, ADARx Pharmaceuticals, Inc. reaches a $2B market value on its first Nasdaq trading day.
- receives_financingSep 25, 2026
ADARx Pharmaceuticals, Inc. received $446M through an upsized IPO in United States on Sep 25th '26.
- hiresSep 21, 2026
ADARx Pharmaceuticals, Inc. announces the appointment of Dr. Chris Storgard as Chief Medical Officer on Apr 2nd '24.
- goes_publicSep 21, 2026
On Sep 21st '26, ADARx Pharmaceuticals, Inc. plans to sell nearly 21.9 million shares at $15-$17 each in an IPO and applies to list on the Nasdaq Global Select Market under ADRX in California.
For institutional investors. Book with your work email.
ADARx Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.